Jazz Pharmaceuticals PLC $JAZZ Holdings Boosted by California Public Employees Retirement System

California Public Employees Retirement System raised its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 124,583 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,915 shares during the quarter. California Public Employees Retirement System’s holdings in Jazz Pharmaceuticals were worth $23,552,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Cardinal Capital Management boosted its position in shares of Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after buying an additional 66 shares during the period. Bessemer Group Inc. raised its position in Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after buying an additional 73 shares during the period. UMB Bank n.a. lifted its stake in Jazz Pharmaceuticals by 12.6% in the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 4.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the transaction, the director owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the sale, the director directly owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. The trade was a 10.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on JAZZ shares. Truist Financial dropped their target price on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Piper Sandler boosted their price objective on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. Leerink Partners upped their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.06.

Jazz Pharmaceuticals Stock Down 1.5%

Shares of Jazz Pharmaceuticals stock opened at $250.41 on Thursday. The firm has a market cap of $15.73 billion, a price-to-earnings ratio of -12,514.24, a P/E/G ratio of 0.22 and a beta of 0.32. The stock has a 50-day simple moving average of $236.40 and a 200-day simple moving average of $202.31. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $255.20. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.